Wuensche, Thomas Erik http://orcid.org/0000-0001-8709-094X
Lyashchenko, Serge
van Dongen, Guus A. M. S.
Vugts, Danielle
Funding for this research was provided by:
Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant agreement No 813528)
Article History
Received: 11 January 2024
Accepted: 21 March 2024
First Online: 11 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: Guus A.M.S van Dongen has the paid (part-time) position of chief scientific officer at LinXis Biopharmaceuticals. No other potential conflict of interest relevant to this article was reported.